[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Aneurysmal Subarachnoid Hemorrhage - Pipeline Review - 2019

December 2019 | 130 pages | ID: A67D3B6DE7A3EN
First View Insight

US$ 1,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Firstview Insight's Aneurysmal Subarachnoid Hemorrhage - Pipeline Review-2019 provides an overview of the pipeline landscape of Aneurysmal Subarachnoid Hemorrhage It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Subarachnoid hemorrhage (SAH) is a life-threatening type of stroke caused by bleeding into the space surrounding the brain. SAH can be caused by a ruptured aneurysm, AVM, or head injury.Treatment focuses on stopping the bleeding, restoring normal blood flow, and preventing vasospasm.Aneurysmal subarachnoid hemorrhage (SAH) is associated with a mortality of more than 30%. Only about 30% of patients with SAB recover sufficiently to return to independent living.

Drug Profile Overview:

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.

Clinical Trial Overview:

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.

Product Development Activity:

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.

Company Overview:

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

Scope
  • The report provides a competitive landscape
  • The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status
  • The report provides the list of companies which are the most active in the pipeline
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery
  • The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities
  • The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report also provides latest news for the past one year
Reasons To Buy
  • To identifying prominent players in the treatment landscape
  • To determine the drivers; barriers and unmet need in the treatment space
  • Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies
  • Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
List of products
  • Acetylsalicylic acid.
  • Sodium nitroprusside.
  • Antihypertensive drugs.
  • L-type calcium channel blockers.
  • Corticosteroids.
  • Nimodipine
  • Labetelol
  • 1. DISEASE OVERVIEW

    1.1. Pathophysiology
    1.2. Symptoms
    1.3. Etiology
    1.4. Diagnosis
    1.5. Etiology
    1.6. Treatment Algorithm
    1.7. Treatment Options

    2. FEATURED NEWS AND PRESS RELEASES, 2018-2030

    3. LIST OF COMPANIES DEVELOPING PRODUCTS FOR ANEURYSMAL SUBARACHNOID HEMORRHAGE

    4. TREATMENT ALGORITHM

    5. CURRENT UNMET NEEDS

    6. MARKET TRENDS

    7. PIPELINE THERAPEUTICS

    8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES

    9. LATE STAGE PRODUCTS (PHASE III)

    9.1 Drug 1
      9.1.1. Product Description
      9.1.2. Research and Development
      9.1.3. Product Development Activities
    9.2. Drug 2
      9.2.1. Product Description
      9.2.2. Research and Development
      9.2.3. Product Development Activities

    10. MID STAGE PRODUCTS (PHASE II)

    10.1 Drug 1
      10.1.1. Product Description
      10.1.2. Research and Development
      10.1.3. Product Development Activities
    10.2. Drug 2
      10.2.1. Product Description
      10.2.2. Research and Development
      10.2.3. Product Development Activities

    11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)

    11.1 Drug 1
      11.1.1. Product Description
      11.1.2. Research and Development
      11.1.3. Product Development Activities
    11.2. Drug 2
      11.2.1. Product Description
      11.2.2. Research and Development
      11.2.3. Product Development Activities

    12. DRIVERS OF ANEURYSMAL SUBARACHNOID HEMORRHAGE

    13. CONSTRAINTS OF ANEURYSMAL SUBARACHNOID HEMORRHAGE

    14. THERAPEUTIC ASSESSMENT

    14.1. Assessment by Route of Administration
    14.2. Assessment by Phase & Route of Administration
    14.3. Assessment by Molecule Type
    14.4. Assessment by Phase & Molecule type
    14.5. Assessment by Target
    14.6. Assessment by Mechanism of Action

    15. COLLABORATIONS AND ACQUISITIONS DETAILS

    16. DORMANT PRODUCTS

    17. DISCONTINUED PRODUCTS

    18. MARKET TRENDS

    19. MARKET OPPORTUNITY ASSESSMENT

    20. UNMET NEEDS

    21. SWOT ANALYSIS

    22. APPENDIX

    23. REPORT METHODOLOGY

    24. CONSULTING SERVICES

    25. DISCLAIMER

    LIST OF TABLES

    Table 1: Marketed Aneurysmal Subarachnoid Hemorrhage drugs, 2019
    Table 2: Sales of Marketed drugs
    Table 3: Patent expiration details – marketed drugs
    Table 4: Number of Products Under Development for Aneurysmal Subarachnoid Hemorrhage
    Table 5: Products under Development by Companies
    Table 6: Late Stage Products
    Table 7: Mid Stage Products
    Table 8: Early Stage Products
    Table 9: Pre-Clinical and Discovery Products
    Table 10: Assessment by Route of Administration
    Table 11: Assessment by Stage and Route of Administration
    Table 12: Assessment by Molecule Type
    Table 13: Assessment by Stage and Molecule Type
    Table 14: Assessment by Target
    Table 15: Assessment by Mechanism of Action
    Table 16: Dormant Products
    Table 17: Discontinued Products

    LIST OF FIGURES

    Figure 1: Marketed and PipelineAneurysmal Subarachnoid Hemorrhage drugs, 2019
    Figure 2: Sales of Marketed drugs
    Figure 3: Patent expiration details – marketed drugs
    Figure 4: Number of Products Under Development for Aneurysmal Subarachnoid Hemorrhage
    Figure 5: Products under Development by Companies
    Figure 6: Late Stage Products
    Figure 7: Mid Stage Products
    Figure 8: Early Stage Products
    Figure 9: Pre-Clinical and Discovery Products
    Figure 10: Assessment by Route of Administration
    Figure 11: Assessment by Stage and Route of Administration
    Figure 12: Assessment by Molecule Type
    Figure 13: Assessment by Stage and Molecule Type
    Figure 14: Assessment by Target
    Figure 15: Assessment by Mechanism of Action
    Figure 16: Dormant Products
    Figure17: Discontinued Products


    More Publications